Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Patients with Coronary Artery Disease Investigated by Angiography

Verena Schroeder; Tushar Chatterjeel; Haresh Mehta; Stephan Windecker; Trinh Pham; Nicolas Devantay; Bernhard Meier; Hans P. Kohler

doi:10.1055/s-0037-1613349

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2002; 88(06): 1020-1025
DOI: 10.1055/s-0037-1613349

Involvement of Thrombin Receptors in the Subject-dependent Variability in Ca2+ Signal Generation

Schattauer GmbH

Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels in Patients with Coronary Artery Disease Investigated by Angiography

Verena Schroeder

,

Tushar Chatterjeel

¹Laboratory for Thrombosis Research and Swiss Cardiovascular Center, Inselspital, University Hospital of Bern

,

Haresh Mehta

¹Laboratory for Thrombosis Research and Swiss Cardiovascular Center, Inselspital, University Hospital of Bern

,

Stephan Windecker

¹Laboratory for Thrombosis Research and Swiss Cardiovascular Center, Inselspital, University Hospital of Bern

,

Trinh Pham

,

Nicolas Devantay

,

Bernhard Meier

¹Laboratory for Thrombosis Research and Swiss Cardiovascular Center, Inselspital, University Hospital of Bern

,

Hans P. Kohler

› Institutsangaben

Abstract

Summary

Due to its role in the balance between coagulation and fibrinolysis, thrombin activatable fibrinolysis inhibitor (TAFI) may be involved in the development of cardiovascular diseases. We studied 362 patients with coronary artery disease (CAD) and 134 control subjects free of CAD, both groups investigated by angiography. TAFI antigen levels were determined in venous and intracoronary plasma samples and were related to metabolic and hemostatic risk factors and extent of coronary atherosclerosis. Venous TAFI levels tended to be higher in CAD patients compared to controls, whereas this difference was significant in intracoronary samples. A subgroup of patients who had not experienced acute myocardial infarction or undergone previous cardiac interventions showed significantly higher TAFI levels in both venous and intracoronary plasma samples. TAFI levels correlated with acute phase reactants indicating a role for TAFI in inflammation. However, TAFI levels did not correlate with extent of coronary atherosclerosis and among the classical cardiovascular risk factors TAFI levels only correlated with total cholesterol and fibrinogen concentration. Our results suggest that TAFI might be a risk factor for the development of CAD.

Keywords

Thrombin activatable fibrinolysis inhibitor - TAFI - procarboxypeptidase - coronary artery disease

Volltext

Referenzen

References
1 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
2 Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation 1996; 93: 1328-30.
3 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombinthrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
4 Von dem PABorne, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
5 Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Review. Thromb Haemost 1997; 78: 386-91.
6 Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
7 Nesheim ME. TAFI. Review. Fibrinol Proteol 1999; 13: 72-7.
8 Mosnier LO, von dem PABorne, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
9 Chetaille P, Alessi MC, Kouassi D, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000; 83: 902-5.
10 Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, Alessi MC. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2000; 20: 2156-61.
11 Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, JuhanVague I. Identification of polymorphisms in the promoter and the 3’ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97: 2053-8.
12 Franco RF, Fagundes MG, Meijers JCM, Reitsma PH, LourenVo D, Morelli V, Maffei FH, Ferrari IC, Piccinato CE, Silva-Ir WA, Zago MA. Identification of polymorphisms in the 5’-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 2001; 86: 510-7.
13 Brouwers GJ, Vos HL, Leebeek FWG, Bulk S, Schneider M, Boffa M, Koschinsky M, van Tilburg NH, Nesheim ME, Bertina RM, Gómez EBGarcia. A novel, possibly functional, singel nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels [Letter]. Blood 2001; 98: 1992-3.
14 Trégouet DA, Aubert H, Henry M, Morange P, Visvikis S, Juhan-Vague I, Tiret L. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Hum Genet 2001; 109: 191-7.
15 Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
16 Cushman M, Folsom AR, Wang S, Heckbert SR, White RH, Aleksic N, Tsai MY, Tracy RP. A prospective study of thrombin activatable fibrinolysis inhibitor (TAFI) concentration and the TAFI -438 A polymorphism in relation to venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Thromb Haemost. 2001 Supplement, XVIII ISTH congress, Paris, abstract OC974.
17 Silveira A, Schatteman K, Goossens F, Moor E, Scharpé S, Strömqvist M, Hendriks D, Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-8.
18 Morange PE, Aubert H, Henry M, Nanni I, Aillaud MF, Alessi MC, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, Juhan-Vague I. Evaluation of TAFI plasma antigen genotypes in myocardial infarction patients and controls from the north and south of Europe (Hifmech study). Thromb Haemost. 2001 Supplement, XVIII ISTH congress, Paris, abstract OC977.
19 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46.
20 Sato T, Miwa T, Akatsu H, Matsukawa N, Obata K, Okada N, Campbell W, Okada H. Procarboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol 2000; 165: 1053-8.
21 Kato T, Akatsu H, Sato T, Matsuo S, Yamamoto T, Campbell W, Hotta N, Okada N, Okada H. Molecular cloning and partial characterization of rat procarboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2000; 44: 719-28.
22 Hudson I, De Bono DP. Levels of carboxypeptidase B (thrombin activatable fibrinolysis inhibitor, TAFI) following thrombolysis with streptokinase. Fibrinol Proteol 1998; 12 (Suppl. 01) 12 (abstract).